GlaxoSmithKline Blacklisted by Chinese Authorities, Suspended From National Drug Procurement

Blacklisting multinational drug companies is part of China's 'decoupling' strategy: Expert

An employee of British drug firm GlaxoSmithKline enters office headquarters in Shanghai. Peter Parks/AFP/Getty Images

Multinational pharmaceutical giant GlaxoSmithKline (GSK) was recently blacklisted by the Chinese authorities and will not be eligible for the country’s national drug procurement program for the next one and a half years.

Through the Chinese drug procurement program, pharmaceutical companies participate in a program of centralized drug procurement that supplies drugs at high volumes and low prices.